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Abstract
Corticotropin-releasing hormone (CRH) is a key player of basal and stress-activated 
responses in the hypothalamic–pituitary–adrenal axis (HPA) and in extrahypothalamic 
circuits, where it functions as a neuromodulator to orchestrate humoral and behavioral 
adaptive responses to stress. This review describes molecular components and 
cellular mechanisms involved in CRH signaling downstream of its G protein-coupled 
receptors (GPCRs) CRHR1 and CRHR2 and summarizes recent findings that challenge 
the classical view of GPCR signaling and impact on our understanding of CRHRs 
function. Special emphasis is placed on recent studies of CRH signaling that revealed 
new mechanistic aspects of cAMP generation and ERK1/2 activation in physiologically 
relevant contexts of the neurohormone action. In addition, we present an overview 
of the pathophysiological role of the CRH system, which highlights the need for a 
precise definition of CRHRs signaling at molecular level to identify novel targets for 
pharmacological intervention in neuroendocrine tissues and specific brain areas involved 
in CRH-related disorders.
Introduction
The neuropeptide corticotropin-releasing hormone (CRH, 
also named CRF) plays a key role in the integration of 
neuroendocrine, autonomic and behavioral responses to 
stress (1). Hypothalamic paraventricular CRH-secreting 
neurons are essential to the stress response driving both 
basal and stress-induced hypothalamic–pituitary–adrenal 
axis (HPA) activation. Besides the hypothalamus, CRH is 
widely distributed in extrahypothalamic circuits of the 
brain where it functions as a neuromodulator to establish 
and integrate a complex humoral and behavioral system 
that regulates multiple aspects of the stress response (1, 
2, 3, 4). Furthermore, a role for CRH as a regulator of 
neuronal structure is being recently appreciated in areas 
of the developing and mature brain (5). CRH system 
dysregulation is critically involved in stress-related 
disorders: psychiatric conditions (i.e. depression, anxiety, 
addictions), neuroendocrinological alterations and 
inflammation and has been reported to influence the onset 
and development of neurodegenerative diseases (6, 7).
CRH is a 41 amino acid peptide first characterized 
from ovine hypothalamus (8). The other members of 
the CRH family (9) in mammals are urocortin 1 (UCN1), 
urocortin 2 (UCN2) and urocortin 3 (UCN3) (Fig. 1). These 
peptide hormones and its receptors are ubiquitously 
present throughout mammalian tissues playing key 
roles in stress-mediated central and local effects. In the 
periphery CRH has an immunomodulatory role, being 
proinflammatory (10).
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Figure 1
The main molecular components of the CRH system (A) Corticotropin-releasing hormone (CRH) is a 41-amino acid neuropeptide generated by proteolytic 
cleavage from a 194-amino acid precursor, followed by the amidation of the carboxyl terminus. (B) Amino acid sequence alignment of mammalian CRH 
family peptides that includes urocortins 1–3 (UCN1, UCN2, UCN3) showing regions of high amino acid conservation in boxes. Identical residues are 
marked in red. (C) Representation of corticotropin-releasing peptide receptors (CRHRs) based on structural data. Within the brain CRHR1 and CRHR2α 
are the two receptors involved. A characteristic feature of class B GPCRs is a large ECD stabilized by three conserved disulfide bridges (white dots 
connected by dash lines) but only CRHR2α contains a pseudo-signal peptide (dark pink). These receptors also differ in their carboxyl-terminal: the last 
four residues of CRHR1 (STAV) conform a PDZ domain, absent in CRHR2 (TAAV). Colored arrows show ligand-receptor interactions, with gray arrows 
indicating lower affinity. CRH binds to both receptors but with higher affinity to CRHR1. UCN1 is a high affinity ligand to both CRHR1 and CRHR2, 
whereas UCN2 and UCN3 are considered selective ligands for CRHR2.
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The CRH system also includes the corticotropin-
releasing hormone-binding protein (CRH-BP) expressed 
in peripheral tissues and the brain. Initially thought to 
bind free CRH and CRH-related ligands attenuating CRH 
receptors activation, its physiological role seems more 
complex and is still being investigated.
CRH and the CRH-related peptides operate through 
CRHR1 and CRHR2, which belong to the class B family of 
G protein-coupled receptors (GPCRs). A wealth of research 
has demonstrated that CRH and UCNs can signal through 
various intracellular pathways that depend on cellular 
context (11). Considering the promiscuous G protein 
coupling of CRHRs, it is not surprising that a plethora 
of molecular components has been implicated in CRHR 
functions, including ERK1/2 and p38 MAPKs, PKA, Akt, 
NFkB, GSK-3b/Wnt, RhoA as well as other important 
signaling molecules such as cAMP, calcium, IP3 and nitric 
oxide/cGMP (10).
Here, we review the principal characteristics of 
the CRH system and describe recent advances on the 
structural and functional features of CRHRs and ligands. 
Recent findings on CRHR1 signaling mechanisms are 
introduced in the context of the emerging model of 
GPCR function, which involves sustained signaling from 
intracellular compartments. We present a brief overview 
of important aspects of the CRH pathophysiology for 
which the identification of novel molecular components 
and mechanisms of CRHRs signaling will impact on 
development of therapies for CRH-related disorders.
The CRH system: CRH, the urocortins and 
their receptors
CRH and the activation of the 
Hypothalamic–Pituitary–Adrenal axis
Hypothalamic CRH neurons drive both basal and stress-
induced HPA activation, the main neuroendocrine 
system involved in stress responses. Stimuli that 
challenge homeostasis originated from visceral input or 
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Figure 2
CRH/CRHR1 action at physiological and molecular levels (A) The HPA axis: CRH and AVP secreted from the hypothalamic PVN activate the release of 
ACTH from pituitary corticotrophs which, in turn, drives the synthesis and release of corticosteroids from the adrenal cortex. Corticosteroids exert a 
negative feedback on the hypothalamus and pituitary suppressing hormone secretion. CRH expression in extrahypothalamic circuits acts as a 
neuromodulator orchestrating a complex humoral and behavioral response to stress. The effect of CRHR1 activation on behavior depends on the brain 
area analyzed. In a sagittal section of the rodent brain, regions associated with increased anxiety-like behavior are shown in yellow and regions 
associated to reduced anxiety are in gray. It is suggested that a delicate balance between CRHR1-controlled circuits is necessary for a proper stress 
response and dysregulation of the system may lead to stress-related disorders. BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; CeA, 
central nucleus of the amygdala; CoA, cortical nucleus of the amygdala; DMH, dorsomedial hypothalamus; GP, globus pallidus; MA, medial nucleus of 
the amygdala; PAG, periaqueductal gray; PVN, paraventricular nucleus of the hypothalamus; RN, raphe nuclei; SN, substantia nigra; VTA, ventral 
tegmental area. (B) Although CRHR1 activation leads to cAMP rise, the time course of this response and the effectors activated downstream vary 
according to the cell context. The cAMP response can either be sustained (hippocampal neurons and fibroblast-derived cell lines) or transient 
(corticotroph cells) and it is only linked to ERK1/2 activation in neuroendocrine or neuronal contexts (hippocampal neurons and corticotroph cells).
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from external environmental changes are communicated 
to the CNS by neurochemical pathways and integrated at 
the hypothalamic level where they reach paraventricular 
(PVN) neurons controlling CRH secretion to the 
hypophyseal portal vessels that access the anterior 
pituitary gland (Fig.  2A). The binding of CRH to 
its receptors activates ACTH release from pituitary 
corticotrophs (1). ACTH stimulates the synthesis and 
release of glucocorticoids from the zona fasiculata of the 
adrenal cortex, cortisol in primates and corticosterone in 
rodents. The biological effects of glucocorticoids support 
the adaptation to stress-induced demands by controlling 
energy metabolism (12, 13). The adaptive function of 
the HPA depends on the negative feedback mechanisms 
that bring the HPA to baseline levels. Corticosteroids are 
released in a pulsatile ultradian pattern that may vary in 
amplitude and frequency under stressful conditions (14).
Extrahypothalamic CRH: organization and integration 
of the stress response
Intracerebroventricular CRH administration lead to 
anxiety-like behavioral and autonomic effects besides 
increasing ACTH release (15, 16, 17, 18). Behavioral 
aspects of the response seem independent of endocrine 
HPA axis–driven responses, since anxiety-related outcomes 
persisted in hypophysectomized rats (19). The differential 
expression of CRHRs and its ligands throughout the brain 
reflects the different actions that CRH exerts at the CNS 
level. A detailed anatomical map of expression of the CRH 
system components (ligands and receptors) in the CNS has 
been achieved integrating data obtained with a variety of 
technical approaches (see a detailed review in (20)).
Different than classic neurotransmitters, it is 
now accepted that CRH and its related peptides act as 
neuroregulators: without affecting synaptic efficacy 
or strength, they activate cell signaling processes that 
facilitate or depress neurotransmitters effect within specific 
neuronal circuits (21). The CRH system is anatomically 
and functionally connected with monoaminergic circuits 
that act in concert to convey stress signals to different 
brain areas to elicit a variety of responses to stress (21). The 
family of CRH and peptides and monoamines act through 
GPCRs, which rapidly modulate downstream effectors 
translating increases of ligands into altered functioning 
of neurons that express these receptors. CRH modulation 
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of norepinephrine release, mainly at the locus coeruleus 
(LC), is considered to underlie the emotional bases of the 
stress response (22).
The negative feedback exerted by glucocorticoids inhibits 
ACTH and CRH release at the pituitary and hypothalamus, 
respectively. This critical feature of the HPA axis is lost in 
ACTH-secreting adenomas (23) and in some depressed 
patients (24), creating a hypercortisolemic state. However, 
in extrahypothalamic circuits, as in the central nucleus of 
the amygdala (CeA), glucocorticoids action stimulates rather 
than inhibit CRH synthesis (see (25) for references).
CRH and UCNs are known to regulate neuronal 
excitability by modulating ionic currents. CRH-activated 
CRHR1 was found to increase neuronal excitability 
of hippocampal CA1 pyramidal neurons through a 
mechanism dependent on L- and T-type calcium channels 
and voltage-gated potassium channels but independent 
on intracellular calcium rise (26). CRH excitatory action 
was also described in the LC, where cAMP/PKA-dependent 
phosphorylation of potassium channels led to a decrease 
in potassium conductance (27). Regarding CRH-like 
peptides, UCN2 reduced intracellular calcium levels by 
inhibiting L-type channels in undifferentiated PC12 
cells (28). In MN9D dopaminergic cells, UCN1 activates 
CRHR1 and modulates T-type calcium channels in a PKC-
dependent manner (29), whereas in HEK293 cells, both 
UCNs and CRH acting via CRHR1 selectively inhibit 
CaV3.2 T-type calcium currents (30).
As expected from the intricate neuronal circuits 
that are interconnected to generate different outputs 
depending on the brain area and neurotransmitter-
specific neurons involved, a variety of effects of CRH are 
observed, although most of the mechanistic aspects of 
these interactions in the brain are not defined yet (31). 
On the other hand, evidence obtained at molecular level 
in cell biology approaches, which may be meaningful 
to understand the outcome of combined effects, are 
not correlated by neurochemical studies or behavioral 
analysis. Integrated molecular cell biology studies and 
neurobiological approaches in animal models will be 
required to unravel the complex physiology of spatially 
convergent systems of the brain.
Structural and functional features of CRH 
and urocortins and their receptors
Phylogenetic studies showed that the origin of CRH and 
its related peptides predates the evolution of tetrapods 
and teleosts, strongly suggesting their essential role to 
maintain homeostasis (32). Two additional CRH-related 
peptides, urotensin I and sauvagine, have been isolated 
from fish and amphibians, respectively (33).
Although CRH was initially described for its function 
as a HPA regulator, CRH is widely expressed in central 
circuits (Fig. 2A) and also in peripheral tissues including 
heart, blood vessels, skin, lung, spleen, pancreas, kidney, 
liver, adipose tissue, digestive tract, testes, ovaries and 
placenta (9). The expression of urocortins (UCNs) in 
the brain is more restricted than that of CRH, being also 
found in pituitary, heart and vasculature, skeletal muscle, 
kidney, adipose tissue, digestive tract and gonads (34).
CRH and UCNs act through two receptors, CRHR1 
and CRHR2, which belong to the class B family of GPCRs 
(Fig.  1C). CRHR1 and CRHR2 are encoded by different 
genes but present a 70% identity at the amino acid level, 
with the major divergence found in their amino-terminal 
domains involved in ligand binding, and therefore, 
responsible for their agonist selectivity (33). The amino 
acid sequences of the intracellular and transmembrane 
domains of CRHRs present 80–85% identity.
Several splice variants of CRHR1 have been identified 
but only one, CRHR1α, presents biological activity and 
is predominantly expressed. In humans, CRHR2 exists 
in three splice variants CRHR2α, β and γ (in mice only 
two isoforms are found) that differ in the amino-terminal 
domain and their tissue distribution (2, 9, 33). CRHR2α 
is the most abundant splice variant in the brain; CRHR2β 
is found almost exclusively in peripheral tissues such 
as retina, ovaries, testes, digestive tract, heart, skeletal 
muscle, lung and skin, whereas CRHR2γ is found in 
septum, hippocampus, amygdala, midbrain, frontal cortex 
and limbic regions of the human brain, but its function is 
still unknown (9, 10). The expression and distribution of 
CRHRs, CRH and UCNs in the different brain regions have 
been extensively reviewed recently (20).
Recent studies demonstrated that different ligands 
acting on the same receptor are determinants of specific 
cellular responses. Counteracting effects of CRH and 
UCN2 on stress effect in physiologically relevant responses 
have been described (35). At the molecular level, a novel 
mechanism by which the endosomal peptidase ECE-1, 
differentially regulates signaling of CRH and UCN1 has 
been recently reported (36).
CRH-binding protein (CRH-BP) is a 37-kDa secreted 
glycoprotein, structurally unrelated to the CRHRs, that 
binds CRH and UCN1 with high affinity (37). CRH-BP 
is found in the liver, placenta and in circulation and 
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co-localized with CRH in some areas of the brain, 
including cerebral cortex and subcortical limbic regions 
(2, 38). Slightly higher plasma levels of CRH-BP have 
been reported in females (39). The role of CRH-BP is still 
not fully understood, and different functions have been 
proposed: to act as a decoy sequestering CRH and UCN1 to 
modulate CRHRs activation, but also to act independently 
of CRH (38) or to function as an escort protein for CRHR2α 
localization (40).
Structural characterization of CRH receptors
GPCRs are the largest family of membrane proteins in the 
human proteome, mediate a myriad of cellular responses 
through interactions with a huge variety of extracellular 
molecules and are major targets for drug development. 
GPCRs share a common transmembrane topology and are 
classified into four major families: A (rhodopsin), B (secretin), 
C (metabotropic glutamate) and frizzled (41). Class B is the 
second largest class and consists of 15 GPCRs that bind 
physiologically relevant peptides. Structurally, class B GPCRs 
are characterized by a large extracellular amino-terminal 
domain (ECD) with a similar tertiary structure composed of 
three-layered α-β-βα fold (‘sushi domain’), stabilized by three 
conserved disulfide bridges, which are part of the binding 
site for ligand recognition (42) (Fig. 1C).
The ‘two-domain’ model is the accepted mechanism 
of ligand interaction with class B GPCRs: the carboxyl 
end of the peptide agonist binds primarily to the ECD 
and the amino portion interacts with the juxtamembrane 
domain, stabilizing the active conformation state of 
the receptor (42). The high-resolution structure of the 
ECD has been solved for CRHR1, CRHR2α and CRHR2β 
bound to ligands (43, 44, 45, 46) providing information 
on ligand recognition and selectivity. The ECDs of the 
three receptors present a similar fold, being the amino-
terminal α-helix shorter in CRHR1 with respect to others. 
In addition, the mature CRHR2α contains a non-cleavable 
pseudo-signal peptide that forms a hydrophobic α-helix 
in the amino-terminus (46, 47). CRHR2α was the first 
GPCR described with a pseudo-signal peptide (47), which 
generates specific signal transduction mechanisms, 
trafficking and internalization processes (48, 49) (Fig. 1C).
A mechanism of compatibility in the amino portion 
of receptors is sufficient for ligand binding recognition 
and discrimination among the family of CRH peptides 
(44, 46). Mutagenesis studies of the extracellular loops of 
CRHR1 showed that the juxtamembrane domain is also 
involved in ligand binding and receptor activation (50).
CRHR1 was the first class B GPCR reported to be 
able to form homo-oligomers at the plasma membrane 
and in intracellular compartments (51). CRHR2β also 
forms oligomers, but CRHR2α behaves as a monomer as a 
consequence of the pseudo-signal peptide presence in the 
mature receptor, which is also believed to cause higher 
intracellular CRHR2α localization and reduced levels in 
the cell surface (51). Moreover, it was proposed that the 
monomer/dimer state influences G protein selectivity, 
whereas CRHR1 exhibited a bell-shaped concentration–
response curve for cAMP, suggesting coupling to Gs and 
Gi; CRHR2α or monomeric CRHR1 showed a monophasic 
concentration–response cAMP curve (48). Analyses of 
functional consequences of CRHRs homo-oligomers in 
physiological contexts await to be addressed.
The formation of heteromers of CRHRs with other 
GPCRs have been proposed to govern the integration of 
different signal transduction systems in complex biological 
responses, such as HPA activation, anxiogenic behavior and 
drug abuse. CRH effect at the pituitary level is amplified 
by arginine vasopressin (AVP), which is produced in the 
supraoptic nucleus and PVN, co-expressed and co-secreted 
from hypothalamic CRH neurons (52, 53). Both CRH and 
AVP neurohormones trigger different signaling pathways 
in pituitary corticotrophs, but the cellular mechanism 
underlying the synergistic effect of CRH and AVP on 
ACTH release is not completely understood. In mammals, 
the physiological actions of AVP are mediated by three 
class A GPCRs – V1a, V1b and V2 (54). V1bR is coupled 
mainly to the phospholipase C (PLC), which increases 
intracellular calcium and protein kinase C (PKC) activity 
in corticotrophs. A crosstalk between AVP and CRH at the 
level of diacylglycerol and IP3 production by the V1bR and 
the accumulation of cAMP by the CRHR1 receptor could 
account, at least in part, for the synergism (55). In avian 
species, the homologous nonapeptide of mammalian AVP 
is arginine vasotocin. Four vasotocin receptors – VT1, VT2, 
VT3 and VT4 – have been identified. Of the four receptors, 
the VT2R appears to be involved in the stress response of 
birds (56). Recently, a direct allosteric interaction between 
vasopressin/vasotocin receptors and CRHR1 was proposed, 
based on FRET and bioluminescence resonance energy 
transfer (BRET) experiments with co-expressed receptors in 
different cellular systems. Although these studies involve 
expression of fluorescently tagged receptors in vitro, 
involvement of hetero-dimerization as a mechanism to 
explain CRH potentiation by AVP is attractive (57, 58, 59).
CRH modulatory effect in dopamine circuits in the 
ventral tegmental area, which are linked to addiction 
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behavior, has been found to be dependent on CRHR1 
activation of the PLC, PKC and PKA signaling pathways 
(60, 61). The ability of CRHR2α and dopamine receptor 
1 (D1R) to physically interact in HEK293T cells may be 
a molecular evidence of a concerted physiological action 
of CRH and dopamine in neurons (62). Oligomerization 
of CRHR1 and orexin1 receptor may provide support for 
pharmacologically significant interactions between CRH 
and orexin-A on dopamine release modulation (63).
CRHRs differ in their carboxyl termini, being a 
PDZ-binding motif (class I, STAV) present in CRHR1 
but not in CRHR2 (64), although the cassette TAAV 
on CRHR2 carboxyl terminus was found to regulate 
CRHR2 internalization in HEK293 cells (65) (Fig.  1C). 
Membrane-associated guanylate kinases (MAGUKs) 
are a family of synaptic PDZ proteins that have been 
reported to interact with CRHR1 and regulate receptor 
trafficking (66, 67). The PDZ domain of CRHR1 allowed 
crosstalk with others receptors, such as 5HT2A serotonin 
receptor (64), suggesting that this motif also plays a role 
in the regulation of the biological response. Evidence 
on CRHR1 and serotonin -5-hydroxytryptamine (5-HT)- 
system interactions have been obtained in terms of both 
molecular and behavioral effects. Enhanced serotonin 
signaling by CRH was shown to require CRH-stimulated 
CRHR1 endocytosis and rapid recycling from endosomes, 
which resulted in increased cell surface expression of 
serotonin receptor (5-HT2R), in both HEK293 cells and 
mouse cortical neurons (64). Using pharmacological 
and optogenetic tools, a recent study described a circuit 
controlling fear and anxiety which was dependent on 
5-HT from the dorsal raphe nucleus acting on CRHR1-
positive neurons of the extended amygdala (68).
The report of the first two class B GPCR crystal structures, 
CRHR1 (69) and glucagon receptor (GCGR) (70), represented 
a major advance in GPCR biology considering the therapeutic 
potential of this class of receptors. A thermostabilized 
transmembrane region of CRHR1 was crystallized in 
complex with a small-molecule antagonist that binds 
deep into the structure. Unlike class A GPCRs, CRHR1 and 
GCGR use distinct determinants for conformational control 
and their transmembrane domains adopt a pronounced 
V-shape, presenting a wider and deeper extracellular cavity 
that presumably forms the peptide-binding site (Fig.  1C). 
The openness of the receptor core somehow explains the 
previous difficulties in identifying small-molecule ligands. 
The solved structures showed distinct subpockets that could 
represent important sites for structure-based drug design 
and the possibility to generate biased agonism to regulate 
the physiological responses (71). The recent structure of the 
full-length class B calcitonin receptor (CTR) in complex with 
peptide ligand and heterotrimeric Gs protein was a huge 
breakthrough, not only for the additional knowledge provided 
but also because it is the first GCPR resolved by phase-plate 
cryo-electron microscopy (72). Important questions about 
the dynamics of the activation mechanism of class B GPCRs 
still remain largely unexplored, but these recent studies may 
open new avenues for rational design of novel ligands with 
therapeutic potential for this class of receptors.
Signaling pathways engaged by CRHRs: 
more complex than initially thought
The canonical GPCRs signaling mechanism is the 
coupling of ligand binding, which stabilizes an active 
conformation of the receptor, to the activation of the 
cytoplasmatic G protein heterotrimer through the 
exchange of GDP for GTP and the functional dissociation 
into Gα-GTP and Gβγ subunits (73, 74). The separated Gα-
GTP and Gβγ subunits regulate the activity of different 
downstream effector proteins. The activated GPCRs 
are substrate of kinase phosphorylation and binding to 
β-arrestins, events that inhibit interaction with G proteins 
and promote endocytosis of receptors via clathrin-coated 
pits (CCPs). The Gs heterotrimer reassembles following 
the hydrolysis of GTP to GDP in the α subunit. Thus, 
acute GPCR signaling was assumed to be restricted to 
the plasma membrane. However, this traditional view 
has been challenged by more recent observations and 
is being replaced by a much more complex signaling 
model for GPCRs and in particular for CRHRs (75, 76, 
77). In the following sections, we review advances in 
the understanding of the molecular signaling cascades 
engaged by the activated CRHRs.
G protein activation
The physiological functions of CRHRs in the CNS and 
the periphery have been mainly associated to an increase 
in intracellular cAMP levels. This is consistent with a 
predominant coupling to Gs, the canonical signaling 
pathway for class B GPCRs (42). However, as observed for 
other members of this class, CRHRs are highly promiscuous 
and capable of activating multiple Gα types (71). Studies 
in tissues with endogenous CRHRs or in recombinant cell 
lines (78, 79, 80) have shown different G protein coupling 
including Gs, Go, Gq/11, Gi1/2 and Gz.
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The characterization of the GPCR/G protein complex 
structure has been achieved for two class A GPCRs, rhodopsin 
and β2 adrenergic receptor (β2AR) (81, 82, 83), and recently 
for class B CTR (72). Activation mechanisms for most class 
B GPCRs have been explored by mutagenesis approaches 
to identify critical residues and motifs involved in the 
recognition and coupling to G proteins. For CRHR1, alanine-
scanning studies determined that the cationic α-helices 
near TMD5 and 6 are crucial for this function and that the 
intracellular loop 3 (ICL3), the juxtamembrane regions as 
well as basic amino acids also contributed as recognition 
sites for Gs, Gi and Gq protein (84). It is remarkable that the 
ICL3 is 100% conserved in all the CRHRs discovered to date 
(9), highlighting its functional importance. Determinants 
of the carboxyl terminus also seem important for G protein 
coupling (72, 78). Finally, the selectivity of G proteins also 
depends on accessory proteins (49). Further exploration of 
G protein activation mechanisms by CRHRs is needed for a 
better understanding of the system.
The cAMP response
Most biological functions of CRH and UCNs, both in 
the CNS and the periphery, have been related to CRHRs 
ability to trigger cAMP production. Earl Sutherland and 
Ted Rall discovered adenosine 3′, 5′-monophosphate 
(commonly referred as cyclic AMP or cAMP) in 1958 as a 
mediator of the function of the hormone adrenaline (85). 
It was rapidly recognized that cAMP mediated the action 
of several hormones and the concept of second messenger 
was introduced. In the words of Sutherland during the 
1971 Nobel Prize winner speech for this revolutionary 
concept developed in the field of endocrinology ‘cyclic 
AMP as a second messenger in hormone action, with the 
hormones themselves acting as first messengers’ (86). 
The wide-ranging effects and variety of cell processes 
regulated by cAMP helped to generate great excitement 
around second messenger function. How is it possible that 
a single molecule mediates so many and often opposed 
physiological processes simultaneously? The existence 
of cAMP microdomains where cAMP is discretely and 
selectively regulated at the subcellular level to ensure the 
fine and precise actions of cAMP was proposed more than 
30  years ago (87). Experimental support for this model 
required the development of live-cell sensors for cAMP 
that allowed spatial and temporal resolution with respect 
to traditional methods. The use of these techniques 
is changing our understanding of cAMP-dependent 
regulation, and in particular, of cAMP generation 
downstream GPCR activation.
Several studies demonstrated that CRHR1 and CRHR2 
activation leads to a rapid accumulation of cAMP (48, 88, 
89). Using a cAMP biosensor based on Förster resonance 
energy transfer (FRET), the CRH elicited cAMP response in 
different physiologically relevant scenarios was recently 
explored (Fig.  2B). In the corticotroph-derived cell line 
AtT20, CRH led to a transient increase in cAMP levels (89). 
On the other hand, the cAMP response elicited by CRH 
in hippocampal and cortical primary cell cultures was 
sustained for at least 10 min after stimulation (90). Notably, 
the hippocampal neuronal cell line HT22 stably expressing 
CRHR1 (HT22-CRHR1) also showed a prolonged cAMP 
response, which stayed elevated for 40 min (89). CRH also 
triggered a sustained cAMP response in the fibroblast-
derived 3T3L1-CRHR1 cells (89), further suggesting that 
the dynamics of cAMP depend on the cellular context. No 
differences were observed in the CRHR1-regulated cAMP 
response when CRH or UCN1 were used as ligands in a 
hippocampal context (90).
The question about the diversity and specificity 
of cAMP-regulated processes can be at least in part 
answered by the existence of different adenylyl cyclases 
(ACs), with different expression profiles and regulatory 
properties. Accumulating evidence suggests that the ACs 
not only generate cAMP, but also orchestrate their own 
microenvironment by recruiting signaling components 
and scaffolding molecules, therefore, contributing to 
the temporal and spatial resolution of the signals (91). 
There are nine G protein–regulated transmembrane ACs 
(tmACs), each with additional regulatory properties (92). A 
second type of AC is the soluble adenylyl cyclase (sAC), an 
evolutionarily conserved enzyme insensitive to G protein 
regulation but directly activated by bicarbonate (93) and 
calcium ions (94, 95). sAC is localized throughout the cell, 
enabling the production of cAMP in different intracellular 
locations close to specific cAMP targets (96).
Perhaps the best-characterized role of sAC is during 
sperm capacitation in testis, but growing evidence 
indicates sAC is ubiquitously expressed and might be 
responsible for cAMP-mediated functions previously 
attributed to tmACs (96, 97, 98, 99). Although GPCR-
mediated cAMP production was thought only dependent 
on tmACs, the involvement of sAC in GPCR signaling has 
recently emerged (97, 100). The study of cAMP response 
elicited by CRH-activated CRHR1 demonstrated that 
both tmACs and sAC are involved in two physiologically 
relevant scenarios, hippocampal HT22-CRHR1 and 
neuroendocrine AtT20 cells (89). Moreover, different 
cAMP sources were found to be involved in different 
signaling mechanisms: tmACs and sAC were required 
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for acute ERK1/2 activation but only sAC was critical 
for sustained phospho-ERK1/2 (89) or CRH-mediated 
neuritogenic effect in HT22-CRHR1 cells (90).
Notably, the participation of sAC depended on the 
GPCR identity (sAC was not engaged downstream βARs 
or PAC1 receptor) and the cellular context (sAC did not 
participate in CRHR1 signaling in fibroblast-derived 
3T3L1-CRHR1 cells) suggesting that sAC is not a general 
mediator of GPCRs (89). Given that sAC activation 
depended on CRHR1-mediated calcium response (89), it 
will be important to further investigate the function of 
sAC considering it might be a key element integrating 
two essential second messengers, cAMP and calcium, 
especially in neurons (101, 102).
The existence of different cAMP effectors also 
contributes to cAMP-mediated response diversification. 
Many of the cellular functions regulated by CRH or 
UCNs have been attributed to protein kinase A activation 
(PKA) (89, 90, 103, 104, 105). Phosphorylation of the 
transcription factor cAMP response element–binding 
protein (CREB) is essential for neuronal transcriptional 
programs in response to multiple external signals. 
Interestingly, CRH activates CREB in an ERK1/2-
independent, sAC- and tmACs-dependent mechanism in 
HT22-CRHR1 cells (90). After the identification of EPACs 
(exchange protein activated by cAMP), their activity has 
also been reported to mediate cAMP-dependent CRHR1 
(89, 106) and CRHR2 (104) cellular responses. A plethora 
of signaling mechanisms is modulated by cAMP, but 
MAPK activation has received special attention in the 
context of CRH and UCNs function.
The development of biosensors capable of monitoring 
cAMP and cAMP effectors activity in live cells became 
valuable tools to understand the signaling mechanisms 
engaged by CRHRs that may contribute to the general 
comprehension of GPCRs function. Remarkably, these 
imaging techniques allow the real-time measurement of 
cAMP in live cells and in more physiological systems, 
such as brain slices. They can be combined with 
electrophysiological recordings to decipher the reports in 
the neurobiology of CRH with simultaneous molecular 
mechanism exploration.
ERK1/2 activation
The MAPKs cascades consist of a module of three kinases 
(MAPKKK-MAPKK-MAPK), activated by a great variety of 
signals. A major role of the MAPK ERK1/2 pathway has 
been recognized in CRHRs biological action. ERK1/2 is 
widely distributed in the brain and is considered a central 
regulator of the molecular processes involved in learning, 
memory, neuronal plasticity and also, during the response 
to stress (see (107) for references).
In AtT20 cells, the cAMP-dependent activation of 
ERK1/2 was critical for the expression of POMC, the 
ACTH precursor (103, 106). In addition, the in vivo 
intracerebroventricular CRH administration activated 
ERK1/2 in specific brain regions functionally involved 
in information processing and behavioral aspects of the 
stress response, such as hippocampus and basolateral 
amygdala (BLA, (108). The molecular mechanisms 
underlying ERK1/2 activation in a hippocampal neuronal 
context have been investigated, using HT22-CRHR1 cells 
as a cellular model. The temporal pattern of ERK1/2 
phosphorylation in response to CRH was biphasic, with 
a first peak 3–6 min after stimulation and a second phase 
that remained activated for at least 60 min after CRH 
addition (105). Importantly, in this hippocampal context, 
ERK1/2 activation was dependent on cAMP levels in 
response to CRH (89, 105) (Fig. 2B).
Considering that the MAPKKK B-Raf, main activator 
of the ERK1/2 pathway, also acts as a scaffold for 
assembling signaling complexes (109, 110), a proteomic 
analysis of B-Raf interactome was performed to unravel 
the cellular components potentially relevant for ERK1/2 
pathway regulation in neurons (76). The role of a subset 
of B-Raf-interacting proteins mediating CRHR1 activation 
was evaluated (105). Using this approach, it was shown 
that at least two distinct mechanisms mediate ERK1/2 
activation, one dependent on G protein activation 
and a second regulated by CRHR1 internalization and 
β-arrestin2 (105). The observation of this biphasic ERK1/2 
activation for several GPCRs has helped to establish a 
new paradigm in GPCR signaling, where signals are not 
exclusively mediated by G protein activation but also by 
G protein-independent pathways (111), as discussed in 
the next section.
In contrast to the stimulatory effect of cAMP on 
ERK1/2 pathway in neuroendocrine (103, 106) or 
neuronal systems (89, 105, 112), there are contexts 
where an increase in cAMP is not linked or even inhibits 
ERK1/2 activation (113). In fibroblastic-derived cell lines, 
HEK293-expressing CRHRs (65, 104, 114) and 3T3L1-
CRHR1 (89), myometrium and breast cancer (114, 115) 
ERK1/2 is activated in response to CRH and UCNs without 
cAMP involvement. In addition, even in cellular systems 
where cAMP regulates ERK1/2 phosphorylation, there 
are signaling cascades and CRH functions regulated by 
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cAMP that are independent of ERK1/2 (90), revealing the 
complexity of the signaling networks.
Small G proteins
Small G proteins are a superfamily of monomeric 
20–30 kDa GTP-binding proteins that act as molecular 
switches, cycling between an active GTP-bound state and 
an inactive GDP-bound state. Its regulation relies on the 
balance between the activity of guanosine nucleotide 
exchange factors (GEFs) that facilitate the exchange of 
GDP for GTP and GTPase-activating proteins (GAPs), 
which increase the intrinsic rate of GTP hydrolysis. 
This superfamily can be classified into five subfamilies 
according to structure similarity and function: Ras, Rho, 
Arf, Rab and Ran family GTPases (116).
CRH-stimulated CRHR1 leads to the activation of 
two members of the Ras family (Ras and Rap1) and both 
proteins are part of the B-Raf complex responsible for 
ERK1/2 activation in a hippocampal neuronal context 
(105). Taking this into account, it would not be surprising 
to find other members of this superfamily or even 
modulators as binding partners of the MAPKKK B-Raf.
Among small GTPases, Rho family is involved in 
cytoskeletal organization and dynamics regulation, being 
a common effector of signaling mechanisms associated 
with cytoskeletal rearrangements and cell motility. 
Recent studies have shown that CRHR1 activation plays 
a role in neuronal architecture, but the exact nature of 
such modulation is still not clear due to controversial 
evidence. In the LC, this effect seems ligand dependent: 
CRH stimulates growth and arborization of LC neuronal 
processes, whereas UCN2 has an inhibitory effect (117). 
These opposing outcomes might be explained by the 
fact that each ligand triggers distinct signaling pathway 
downstream CRHR1. CRH action requires PKA, ERK1/2 
and Rac1, whereas UCN2 effect is mediated by PKC 
and RhoA (117). CRH/CRHR1-mediated promotion of 
neurite outgrowth through PKA- and ERK1/2-dependent 
mechanisms has also been reported in the noradrenergic 
LC-like CATH.a cell line and Purkinje cells in cerebellar 
slices (112, 118). Reduced dendritic arborization of 
neurons of the developing hippocampus requires the same 
signaling cascade (119). The cell model used in each case 
may account for the variety of effects and actors involved 
in CRHR1-mediated cytoskeletal changes.
Stress impairs learning and memory via mechanisms 
that disrupt the integrity of hippocampal dendritic spines. 
Although CRH action on spine density and distribution 
seems to depend on the brain region analyzed, the 
regulation of RhoA activity is consistently involved as 
its consequent remodeling of actin cytoskeleton. These 
alterations in neuronal architecture generate changes 
in both the number and strength of synapses that 
could account for cognitive impairment associated with 
stress-related pathologies (120). Future studies regarding 
Rho GTPases involvement in CRH signaling need to be 
carried out at a molecular level to define CRH-triggered 
mechanisms regulating neuronal morphological changes.
Gβγ-mediated signaling
Originally, it was thought that the Gβγ dimer was only 
necessary for the inactivation of Gα subunits given that 
it prevented spontaneous Gα activation in the absence 
of receptor stimulation and allowed the interaction 
with the receptor for new cycles of signaling. Later on, 
reconstitution studies showed that Gβγ is required for 
GPCR-mediated nucleotide exchange (121). Gβγ binding 
to Gα was either required to target Gα to the membrane 
(122) or to organize Gα subunit structure so that it 
could become a substrate for receptor interactions (121). 
However, it is now well established that Gβγ dimers 
can activate their own signaling pathways downstream 
of GPCRs. As they lack a catalytic site, Gβγ dimers are 
considered modulators of protein activity through the 
interaction with their effectors in sites known as hot 
spots (121).
Remarkably, Gβγ-mediated MAPK activation has 
already been described in various systems. Using COS-7 
cells as model, it was shown that Gβγ complex is involved 
in muscarinic receptor 1- and -2 mediated ERK1/2 and 
JNK activation as well as ERK1/2 activation downstream of 
β2AR (123). The use of dominant negative mutant forms 
of several Rho GTPases abolished Gβγ stimulatory action, 
suggesting that these proteins mediate the effects of Gβγ 
complex observed (124, 125). Little is known about Gβγ 
role in CRHR signaling. In HEK293 cells, Gβγ stimulated 
ERK1/2 phosphorylation in response to CRHR1 activation 
by UCN1 (126). There is also evidence of a stimulatory 
effect of Gβγ regarding CRH/CRHR1-mediated CREB 
activation in primary cultures of striatal neurons and 
pyramidal neurons of the hippocampus (127, 128).
For GPCRs such as parathyroid hormone receptor 
(PTHR1) or β2-adrenergic receptor (β2AR) the involvement 
of Gβγ complex on signaling has been studied in detail 
(129, 130), leading to the discovery of non-canonical 
pathways regarding receptor transactivation and 
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endosomal signaling/cAMP production. This opens a 
whole new scenario for GPCR signaling that is definitely 
worth addressing for the CRH system.
CRHRs endocytosis: desensitization and 
signaling
In the classical paradigm, agonist-activated G protein-
mediated signaling is terminated at the plasma membrane 
by a mechanism that involves receptor internalization. The 
phosphorylation of Ser/Thr residues of the cytoplasmic 
loops and tail of the GPCRs promotes the recruitment 
of β-arrestins, which destabilize the interactions with G 
proteins and bind AP-2 and clathrin, causing the whole 
complex to be internalized. Thus, in this model, there is a 
temporal correlation between receptor internalization and 
the attenuation of the GPCR signaling (111). Although 
there is no doubt about the role of endocytosis mediating 
long-term signal extinction, numerous studies have 
helped building an new picture in which endocytosis 
modulates signaling, enabling cells to regulate the spatial 
and temporal control of the signal (76, 131).
Following agonist-induced activation, CRHRs undergo 
rapid endocytosis, reducing the number of receptors 
present on the cell surface and diminishing the cellular 
responsiveness to the extracellular ligand. Due to the lack 
of reliable antibodies to detect endogenous expression of 
CRHRs (132), kinetics of receptor endocytosis have been 
mainly studied in cell models transfected with tagged 
forms of the receptors. In HT22-CRHR1 cells, a significant 
fraction of CRH-activated CRHR1 was internalized 
after 5 min of stimulation and remained constant for 
at least 30 min (89). Similar results were observed in 
HEK293-CRHR1 cells and cortical neurons after 10 min 
of CRH addition. Internalized CRHR1 was found to be 
accumulated in intracellular clusters (89, 105, 133). 
Regulated endocytosis of CRHR2α (134) and CRHR2β (65) 
has also been reported.
After receptor activation, desensitization mechanisms 
have been extensively reported in line with the 
physiological notion that high ligand levels promote 
the attenuation of the response. This process has been 
described in cell lines overexpressing recombinant 
CRHRs, human myometrial cells, rat pituitary, human 
retinoblastoma and neuroblastoma cell lines Y79 and IMR-
32 (see (9) for references). Desensitization was also found 
dependent on specific ligands activating CRHRs (135). 
CRH and UCN1 differential regulation of CRHR1 recycling 
and resensitization has been recently demonstrated to be 
dependent on the endosomal peptidase ECE-1 (36).
The mechanism of desensitization has received 
special attention considering that the failure of this signal 
regulation during recurrent exposure to stress may be 
causally related to pathological conditions (20) or the sex 
differences observed in the receptor rate of internalization 
could explain the increased vulnerability of females to 
stress-related disorders (136). Sex-dependent mechanisms 
have also been described in CRHR2 and UCN1-mediated 
stress-mediated inflammation responses (137, 138).
Phosphorylation of the cytoplasmic loops and tail 
of the activated GPCRs is catalyzed predominantly by 
G protein-coupled receptor kinases (GRKs) (139, 140). 
CRHR1 phosphorylation involved in desensitization was 
reported to be mediated by GRK3 and GRK6 in HEK293 
(88) and GRK3 in Y79 neuroblastoma cells (141), while 
in AtT20 cell line GRK2 was the main kinase involved 
(142). Notably, the kinetics of signal desensitization and 
recovery depended on the cell system studied. CRHR1 
endogenously expressed in AtT20 corticotrophs (143) or 
recombinantly overexpressed in HEK293 cells resensitize 
within 1–2 h after CRH stimulation (88). However, a full 
recovery of the response was achieved only after 24 h post 
CRH addition in neuroblastoma IMR-32 or retinoblastoma 
Y79 cells (144, 145). Although trafficking and degradation 
rates of CRHRs may depend on the analyzed systems, 
these differences might also be explained by a differential 
expression of GRKs and arrestins in different cell types 
(146). Therefore, relative expression of modulators of 
GPCR internalization may influence CRHRs activity in 
physiological contexts of CRH action.
β-arrestins: GPCR internalization and organizers of 
signaling complexes
Arrestins were originally recognized for their ability 
to bind the activated GPCR and ‘arrest’ signaling via G 
proteins. However, over the years, it has been appreciated 
that arrestins not only prevent G protein activation but 
also have the capacity to function as multifunctional 
adaptor proteins that modulate endocytosis and transduce 
signals to multiple effector pathways (147, 148). Arrestins 
critically regulate GPCR desensitization: they are recruited 
to phosphorylated GPCRs and initiate internalization 
by linking the receptor to the adaptor protein subunits 
of CCPs. Remarkably, arrestins also serve as scaffolds of 
a diverse group of signaling mediators, such as MAPKs, 
nuclear factor-κB (NF-κB) and phosphoinositide 3-kinase 
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(PI3K) (111, 149, 150). The dual role of β-arrestins as 
attenuators and also as propagators of the signal changed 
the relatively simple previous model of GPCR signaling 
involving G protein activation followed by endocytosis-
dependent desensitization.
Several studies have shown that CRHRs activation 
promotes a rapid recruitment of β-arrestins to the plasma 
membrane and this favors receptor internalization 
(65, 88, 133, 146, 151). The relative contribution of 
β-arrestin-1 and β-arrestin-2 in CRHR1 internalization 
has been investigated. Ligand-activated CRHR1 binds to 
both β-arrestins (146) but preferentially to β-arrestin-2 in 
HEK293, CHO-K1 cells and in primary cortical neurons 
transfected with CRHR1 (133, 143, 146). It has also been 
shown that CRHR2α (134) and CRHR2β (65) preferentially 
recruit β-arrestin-2 once activated.
In line with β-arrestin dependence of agonist-induced 
CRHR1 endocytosis, inhibition of β-arrestin function 
diminished (88), whereas β-arrestin overexpression 
augmented (146) CRHR1 internalization. Although both 
GRKs and β-arrestins play important roles regulating 
CRHR1 desensitization, β-arrestin binding seem to 
be mediated by both phosphorylation-dependent 
and -independent motifs (146, 151) suggesting the 
existence of complex regulatory mechanisms of receptor 
internalization. Sex differences in β-arrestin-2 recruitment 
to CRHR1 have been observed (152). In LC neurons, 
the level of association between β-arrestin-2 and CRHR1 
under unstressed conditions was comparable in males 
and females, but stress exposure only induced β-arrestin-2 
recruitment and subsequent CRHR1 internalization in 
males. In addition, there was an enhanced coupling to 
Gs of CRHR1 in female neurons suggesting a model of 
sex-biased signaling. The sex differences in receptor 
association with G proteins and β-arrestin-2 do not 
depend on circulating gonadal hormones but may arise 
from posttranslational modifications. These gender 
differences in CRHR1 signaling and trafficking suggest 
a deficient adaptation to excessive exposure to CRH in 
females, which may contribute to the increased incidence 
of stress-related psychiatric diseases in females (136).
The finding of non-canonical GPCR signaling 
pathways mediated by β-arrestins has represented a true 
paradigm shift. Moreover, the biochemical data suggesting 
that cascades activated by β-arrestins may have distinct 
physiological outcomes from those activated by G proteins 
have led to great pharmacological efforts in developing 
biased agonists, which selectively activate specific signaling 
pathways given their therapeutic potential (111).
By inhibiting β-arrestin function, it was shown that 
CRHR1 activates ERK1/2 in a mechanism dependent on 
β-arrestin2 in HT22-CRHR1 cells (105). Interestingly, 
the β-arrestin-dependent ERK1/2 phosphorylation had 
different temporal characteristics with respect to the early 
ERK1/2 activation mediated by G proteins. The sustained 
β-arrestin-mediated phospho-ERK1/2 is observed after 
20 min of ligand addition. Moreover, the late ERK1/2 
activation phase was also dependent on CRHR1 
internalization, suggesting that β-arrestin functioning 
as a signaling scaffold is linked to its role in regulating 
receptor internalization (105).
The activation of the MAPK cascade was the first 
pathway to be described dependent on β-arrestin function 
downstream an activated GPCR (149, 153). It is proposed 
that β-arrestins function as scaffolds allowing the 
organization of signaling complexes. β-arrestin-mediated 
ERK1/2 phosphorylation is likely to be physiologically 
relevant as this ERK1/2 pool seems to have different 
consequences compared to the pool activated by G 
proteins (154). It has been reported to play a role in 
chemotaxis and cytoskeletal rearrangements (155, 156) as 
well as in cardiac function (157).
The mechanistic basis of β-arrestin-mediated 
signaling has remained unclear for a long time. Recently, 
several studies have made important progress in the 
understanding of this process. It is now recognized that 
β-arrestins exist in a large array of conformations, are 
very dynamic and can interact with more partners that 
previously thought (158). Moreover, GPCRs can impose 
conformational signatures on β-arrestins and β-arrestins 
remain active following receptor dissociation (159). These 
findings addressed the previous contradictory observations 
of β-arrestin-mediated ERK1/2 activation stimulated by 
GPCRs that interact transiently with β-arrestins and do 
not co-localize in endosomes, such as CRHR1 and CRHR2, 
and even GPCRs that are poorly phosphorylated and 
weakly internalized, such as β1-adrenergic receptors (160).
In addition to previously mentioned G proteins, 
GRKs and β-arrestins, GPCRs interact with numerous 
proteins, including other GPCRs, GPCR accessory 
proteins and intracellular proteins, which modulate 
signaling, expression and pharmacological profiles 
of GPCRs. GPCR biosynthesis, trafficking to the cell 
surface, compartmentalization to specific membrane 
microdomains and endocytosis are processes regulated 
by accessory or escort proteins (161). Co-expression of 
receptor-activity-modifying protein RAMP2 and CRHR1 
increased the presence of both proteins at the plasma 
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membrane and changed the G protein coupling profile, 
enhancing Gi, Gq and G12/13 binding (71). Many 
other accessory proteins have been reported to interact 
with and modulate GPCRs, including regulators of G 
protein signaling (RGS), calpain and 14-3-3 proteins 
(162). Understanding these additional layers of GPCR 
regulation may represent opportunities for drug 
development.
Prolonged signaling
CRHR1 continues to signal after internalization 
It was assumed for a long time that the internalized 
GPCRs were unable to signal. This premise was built upon 
technical limitations as well as experimental evidences, 
i.e. the observation that β-arrestins sterically blocked G 
protein binding to GPCRs. However, results accumulated 
over the past several years support the alternative 
hypothesis that signaling can be initiated from endosomes. 
The first evidence of GPCR signaling from endosomal 
compartments was in yeast, where the activation of the 
Gα protein subunit GPA1 in intracellular membranes 
promoted a late signaling phase of the GPCR Ste2p 
(163). Prolonged GPCR signaling in mammalian cells was 
suggested in three independent reports investigating the 
mechanisms activated by different receptors. It was shown 
that the activation of GPCRs for parathyroid hormone 
(PTH, (164) and thyroid-stimulating hormone (TSH, (165) 
produced a sustained cAMP response, poorly reversed 
after ligand removal and temporally overlapped with 
receptor endocytosis. The observation of the prolonged 
effect of the sphingosine-1-phosphate receptor (S1P1R) 
agonist, extended this model to the Gi-linked signaling 
(166). This prolonged signaling engaged by GPCRs was 
referred as non-canonical, considering that acute G 
protein activation restricted to the plasma membrane was 
the classic signaling pathway. However, this persistent 
signaling has been subsequently reported for other GPCRs, 
including peptide hormone receptors, such as glucagon-
like peptide 1 receptor (GLP1R) (167), pituitary adenylate 
cyclase activating polypeptide (PACAP) type 1 receptor 
(168), vasopressin receptor (V2R) (169) and monoamine 
receptors such as dopamine receptors (170) and β2AR (171, 
172). These recent evidences strongly suggest that this 
would be a general mechanism instead of an exception, 
and led to reevaluate the previous assumptions. A much 
more complex signaling mechanism engaged by GPCRs 
is emerging, where endosomes act as signaling platforms 
that allow spatial and temporal control of the signals 
originated at the plasma membrane and the fine tuning 
of the biological response (131).
The use of FRET-based biosensors to study CRHR1 
signaling revealed that the duration of the cAMP 
response elicited by CRH depends on the cellular 
model of study (Fig.  2B). Although in AtT20 cells the 
cAMP response is transient (89), primary cortical and 
hippocampal neurons as well in HT22-CRHR1 cells 
show a more prolonged response (89, 90). The fact that 
in a hippocampal context, the time course of CRHR1 
internalization overlapped that of cAMP production 
(89) and that endocytic blockade reduced the activation 
of cAMP-dependent signaling cascades, such as ERK1/2 
(105), suggested that CRHR1 also continued to signal 
once internalized. By monitoring the cAMP response 
to CRH in live cells, it was shown that endocytosis 
blockade by inhibiting dynamin reduced cAMP levels 
(89). Interestingly, endocytosis inhibition did not 
affect the initial rise in cAMP levels, but the differences 
were significant at later time points, when receptor 
endocytosis was evident. Also, inhibition of dynamin 
did not alter cAMP production elicited by receptor-
independent activation of ACs with forskolin, showing 
that receptor activation was necessary for this mechanism 
(89). Although CRH-activated CRHR1 stimulates a 
nearly simultaneous rise in intracellular calcium levels 
in addition to the cAMP increase, endocytosis did not 
regulate the calcium response (89).
Mechanisms of sustained GPCR signaling The 
findings of prolonged GPCR signaling support the 
existence of mechanisms that enable pathway activation 
from endosomal stations, different from those occurring at 
the plasma membrane. Using conformational biosensors 
based on single-chain antibodies or ‘nanobodies’, it has 
been demonstrated for β2AR that endosome-localized 
receptors are active and can engage new cycles of Gs 
activation (171).
Because β-arrestins binding to the transmembrane 
core of the receptor overlaps the binding site of G proteins 
(173, 174, 175) it was assumed that signaling pathways 
dependent on G protein activation ended when the 
GPCR-β-arrestin interaction was formed. The mechanisms 
by which G protein activation from endosomes occurs 
are only starting to be understood. For GPCRs that 
form transient complexes with β-arrestins two phases 
of G protein activation were observed, the first at the 
plasma membrane and the second following receptor 
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internalization after the endocytic vesicle uncoating from 
β-arrestins and CCP-associated components (171).
These observations were more difficult to reconcile 
for those GPCRs that form stable complexes with 
arrestins and that internalize together into endocytic 
vesicles. Recently, it has been observed that β-arrestins 
also assume a ‘tail’ conformation, in which they are only 
bound to the carboxyl-terminal tail of the receptor (173) 
allowing the GPCR to interact simultaneously with both 
Gs and β-arrestins (176). These results have provided a 
molecular basis for sustained G protein signaling from 
endosomes.
Studies on GPCRs for which β-arrestins promote rather 
than attenuate cAMP production, such as PTHR and V2R, 
have also contributed to our current understanding of the 
molecular events involved in regulating GPCR signaling 
after receptor internalization. A particular receptor 
conformation is needed to maintain Gs signaling from 
endocytic vesicles. This active conformation is achieved 
when PTH is the ligand, but there is a different active 
conformation stabilized by PTHrP that mediate more 
transient responses (75, 164). It has been proposed that 
cAMP generation by PTH-activated PTHR1 is maintained 
in early endosomes by a positive feedback mechanism, 
where arrestin-dependent activation of ERK1/2 inhibits 
phosphodiesterases (PDEs) and favors the cAMP response 
(177). In addition, the formation of PTHR1-β-arrestin-Gβγ 
complexes might promote new cycles of Gs activation and 
prolong cAMP signaling (129). β-arrestins also promoted 
a sustained cAMP generation in response to vasopressin-
activated V2R, a class A GCPR (169). Again, these results 
challenge the classical role of β-arrestins in desensitization 
of GPCRs, showing that they might promote specific 
signaling mechanisms.
For CRHR1, the study of the molecular mechanisms 
engaged by different cAMP sources led to the 
characterization of an alternative mechanism for 
endosome-based GPCR signaling (Fig. 3). In response to 
CRH, the endocytosis-dependent cAMP generation and 
ERK1/2 activation critically depend on sAC activity. cAMP 
produced by both tmACs and sAC is required for the 
early phase of ERK1/2 phosphorylation triggered by CRH-
stimulated CRHR1, but only sAC activity is essential for 
the sustained internalization-dependent phase in HT22-
CRHR1 cells (89). Thus, the existence of different ACs, with 
specific regulatory properties and subcellular distribution 
create a new layer of complexity. These results show that, 
at least in the case of CRHR1, the spatial resolution of the 
signals is achieved by the involvement of an alternative 
source of cAMP instead of just by the formation of specific 
signaling complexes along the endocytic pathway (178).
The fact that the endocytosis-regulated ERK1/2 
phosphorylation also depends on β-arrestin2 (105) raises 
the question of whether β-arrestins are also involved in 
cAMP generation from endosomes in response to CRH, 
and if sAC and β-arrestin are functionally connected. It 
is interesting that the endocytosis-dependent component 
of the cAMP production in response to CRH was not 
affected by ERK1/2 pathway inhibition (89), different to 
what was observed for PTHR1 (177). This suggests that the 
activation of signaling pathways from endosomes might 
occur through a variety of mechanisms that coexist or 
that are differentially involved depending on the GPCR 
or the cellular context.
Future questions: significance of endosomal signaling
The recent results presented here reveal new aspects of 
CRHRs signaling mechanisms that are only beginning 
to be explored. In the light of an emerging view of 
GPCR function many important questions await to be 
addressed.
If the CRHR1 continues to signal once internalized, 
which mechanisms are involved in signal termination? 
Recent work suggests that mechanisms that regulate the 
post-endocytic fate of GPCRs are crucial (76, 77, 179). 
Once endocyted, receptors enter a dynamic and elaborated 
tubulovesicular endosomal network where protein 
processing and sorting occurs. In general, following signal 
termination the inactive receptor can be directed to the 
lysosome for degradation or to recycling systems either 
directly to the plasma membrane or via the trans-Golgi 
network (TGN) (131).
The superfamily of Rab GTPases regulate various steps 
of membrane trafficking, being involved in targeting, 
tethering and docking of endosomal vesicles. Rab proteins 
have been demonstrated to modulate intracellular 
trafficking of GPCRs (see (180) for references). The 
endosome-based cAMP generation by PTHR1 has been 
localized in Rab5 early endosomes (164). Moreover, the 
signal turn off coincides with the release of β-arrestins and 
the engagement of the cargo-sorting retromer complex, 
which regulates protein sorting from early endosomes 
to the TGN (177). A negative feedback mechanism that 
includes PKA-regulated v-ATPase-mediated endosomal 
acidification is critical for shifting active PTHR1-arrestin 
to inactive PTHR1-retromer complexes (181). A key 
role of the retromer complex was also described for the 
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Figure 3
A new mechanism of CRH-activated CRHR1 signaling. In the classical model, CRHR1 activation by CRH is followed by a rise in cAMP mediated by G 
protein–dependent tmACs. Binding of β-arrestin2 to agonist-activated CRHR1 triggers receptor internalization leading to termination of agonist-
activated G protein-mediated signaling. In the emerging model discussed in this work, an atypical pool of cyclic AMP is generated by soluble adenylyl 
cyclase (sAC) in response to CRHR1 activation in addition to cAMP generated by tmACs. In hippocampal neuronal cells cAMP was found to activate 
specific signaling pathways that are dependent on the source (tmACs or sAC) and cellular location (cell surface or endosomes) of the cAMP generation. 
In particular, sAC was critical for endosome-generated cAMP in response to CRH.
Review C Inda et al. Molecular mechanisms of 
CRH signaling
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:R112R112–R120
termination of the endosomal signaling from V2R (169). 
In the case of β2AR, it was recently shown that signaling 
from endosomes occurs exclusively in recycling tubules, 
pointing out again to the existence of mechanisms that 
allow spatial control of the signal (179). Internalization 
of activated CRHR1 in Rab5-positive early endosomes in 
HEK293 cells and in cortical neurons has been reported 
(133, 182), but simultaneous presence of CRHR1 and 
β-arrestins in endocytic compartments depended on the 
cell type (133). The nature of the intracellular domains 
that activated CRHR1 transits once internalized, with 
or without signaling proteins, needs to be determined 
in neuroendocrine and hippocampal neuronal contexts 
to define the mechanisms of both acute and sustained 
CRH signaling. The involvement of negative feedback 
mechanisms and/or molecular components of the retromer 
in signal termination need to be assessed for CRHR1.
How sAC is integrated in signaling complexes that 
allow the spatial information to be decoded is an important 
issue not explored yet. For example, whether sAC forms 
a physical complex with CRHR1 or an ‘activation at a 
distance’ mechanism is involved, as recently described 
for β-arrestins and β1AR (160), is still an open question. 
Recently, sAC was found associated with the A-kinase 
anchoring protein ezrin (183) and involved in specific 
functions in different subcellular localizations (96). There 
is a growing appreciation that ACs play a critical role 
not only as producers of cAMP but as true organizers of 
signaling complexes, mediating specific cellular functions 
as a core of highly organized microdomains (91).
Using a combination of BRET assay and single 
particle electron microscopy analysis, the formation of 
endosomal ‘megaplexes’ composed of β2AR, β-arrestin, 
and heterotrimeric G protein has been shown (176). New 
BRET biosensors targeted either to plasma membrane or 
endosomes have been recently designed (184). The use of 
the latest high-resolution technologies will certainly have 
a strong impact on the study of GPCR signaling complexes 
at structural level.
Which is the functional significance of the endosome-
based CRHR1 signaling? Are endosome-based signals 
functionally distinct from those initiated from the plasma 
membrane or do endosome-based events represent a spatial 
and/or temporal extension of a signal that is otherwise 
identical to that initiated at the cell surface? Recent evidences 
obtained for GPCRs suggest two main effects of the signals 
initiated in endosomes. First, it has been observed that the 
activation from endosomes extends the duration of the 
responses. It has been shown that the timing of the signal 
regulates physiological processes (164,  165, 185) but the 
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specific roles of this pathway remain to be studied. Second, 
the endosome-based activation seems to provide a spatial 
specificity to downstream signaling mechanisms activated. 
For example, the location of the cAMP production controls 
the repertoire of target genes transcriptionally activated in 
response to β2AR activation (172).
Future studies should also address whether the two 
mechanisms of the biphasic ERK1/2 activation can 
account for different cellular processes. Despite the 
enthusiasm regarding the existence of mechanisms that 
may lead to different outcomes from activated GPCRs, 
whether they have any biological significance in native 
cell types or tissues is still an open question.
Dysregulation of the CRH system
Centrally released CRH plays a critical role in behavioral 
state of anxiety, independently of its effects on the 
pituitary (24). Overexpression of CRH induces stress 
and an anxiogenic-like phenotype in rodents (186), 
whereas suppressing CRH expression has anxiolytic 
effects in both basal and stress-induced anxiety 
(187). Genetic and pharmacological approaches have 
attributed CRH anxiogenic effects to the activation 
of CRHR1 (188,  189). In terms of abundance and 
distribution, CRHR1 is the main CRH receptor in the 
brain, whereas CRHR2 expression is more restricted 
(20). The role of CRHR2 activation mediating anxiety 
and depression has been less clear. Crhr2-knockout mice 
showed an anxiogenic phenotype, increased endocrine 
response, and impaired recovery after stress (190, 191) 
supporting a role of CRHR2 mediating stress recovery 
and the restoration of homeostasis. Similarly, deleting 
all three Ucn1-3 genes induced a susceptibility to the 
effects of stress exposure (192). A recent analysis in 
CRHR2 and UCN3 defective mice suggests that both are 
essential components of the CRH system to successfully 
cope with complex social challenges (193). It is to note 
that recent work using new neurobiological tools, such 
as conditional mutagenesis, viral manipulations and 
optogenetics, has allowed site-specific manipulation 
of CRHR1 and CRHR2 revealing a more complicated 
pattern of CRHRs responses in specific circuits of 
the brain, suggesting that both CRHR1 and CRHR2 
modulate anxiety-like behavior in rodents in a brain 
region-dependent manner. Contrasting findings 
of effects of CRHR subtype activation are observed 
within single brain regions, implicating a highly 
complex mechanism of region dependency and circuit 
specificity, cell type and ligand involvement (20). 
In particular, the involvement of the limbic system 
(hippocampus and extended amygdala) has been the 
focus of many studies, given its central role in stress-
related behaviors, sensory processing of multimodal 
stimuli, learning and memory formation. The effects 
of stress on hippocampal structure and function are 
complex, and exhibit a bidirectional pattern depending 
on duration and intensity of the stimulus (31, 194).
In line with cell- and region-dependent effects, 
mice lacking CRHR1 in glutamatergic neurons show 
reduced anxiety and impaired neurotransmission in the 
hippocampus and BLA, whereas mice lacking CRHR1 
in dopaminergic neurons show increased anxiety-like 
behavior and reduced dopamine release in the prefrontal 
cortex. This differential role for CRHR1 was suggested to 
indicate that, under physiological conditions, CRHR1-
controlled glutamatergic and dopaminergic systems 
might function in an antagonistic manner to maintain 
adaptive responses to stressful situations in balance (132, 
Fig. 2A). In that line, CRH effect on dopamine release in 
the nucleus accumbens was abolished in mice exposed to 
severe stress, which was accompanied by a depression-like 
phenotype evidenced as a shift of the CRH response from 
appetitive to aversive (195).
Clinical studies also support that stress-induced CRH 
actions are mediated through CRHR1 activation (196). 
Recent studies in humans revealed genetic and epigenetic 
variations in the CRH system that may be predictors of 
high vulnerability to neuropsychiatric stress-related 
disorders (197). Collectively, these evidences strengthen 
the notion of a critical function of the CRH system 
in stress-related pathologies, and highlight the need 
of a clear definition of molecular components and 
mechanisms involved in CRH signaling for designing 
new therapies.
Perspectives: CRH signaling as a basis for 
discovery of drug targets
The effects of stress on brain functions ranges from 
behavioral adaptation to enhance survival to increasing 
the risk to develop stress-related psychiatric disorders. 
A dysfunctional CRH system is associated with the 
occurrence of major depression, post-traumatic stress 
disorder, addiction behavior, and anxiety disorders 
(7, 198, 199).
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
DOI: 10.1530/EC-17-0111
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
Review C Inda et al. Molecular mechanisms of 
CRH signaling
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:R114R114–R120
Alteration of the CRH system and chronically 
elevated CRH levels are implicated in human stress-related 
affective disorders (196, 200). Augmented concentrations 
of CRH were found in cerebrospinal fluid from depressed 
(201) and post-traumatic stress disease (202) patients, 
and in some cases were normalized after antidepressant 
treatment (203, 204). Depressed suicide victims showed 
decreased levels of CRHR1 in specific brain areas, 
suggesting desensitization mechanisms due to excessive 
CRH (201, 205).
A number of psychiatric disorders, neurodegenerative 
diseases, behavioral and physiological manifestations 
of alcohol withdrawal, relapse to drug in addictions or 
compulsive eating in obesity -conditions that involve 
genetic predisposition and environmental stressors- have 
been linked to the activity of extrahypothalamic brain 
CRH systems (198). It has been suggested that high chronic 
stress and alterations in the CRH system are connected 
to the onset and development of neurodegenerative 
disorders, such as Alzheimer disease (9, 206). Therefore, 
a search for brain barrier penetrant small-molecule 
compounds to target CRHRs without causing metabolic 
and other side effects by HPA axis suppression is an area 
of active investigation (7). In numerous studies in animals 
and a few studies in humans, CRHR1 has been validated 
as a target modulated for antidepressants (6). However, 
clinical studies with CRHR1 antagonists in depressed 
subjects showed mixed results (52) which might be 
reflecting a need of a deeper understanding of CRHRs 
function to identify molecular targets with therapeutic 
potential.
As presented here, efforts to understand how CRHR1 
exerts these important functions at molecular level 
have revealed new mechanisms of signaling that may 
be relevant in pathophysiological contexts (Fig.  3). A 
precise definition of CRH signaling mechanisms with 
spatial and temporal resolution will enable identification 
of novel targets for pharmacological intervention in 
neuroendocrine tissues and specific brain areas involved 
in CRH-related disorders.
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